PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - Nested Registry 3/Valve-in-Valve

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 197 participants.

Also called NCT03225001

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 197 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03225001
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03225001. Allocation not applicable; no masking; primary purpose treatment. Start 2012-06-11 (actual); primary completion 2016-12-16 (actual). Results posted on 2018-01-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - Nested Registry 3/Valve-in-Valve
Acronym
PII NR3/ViV
Condition
Aortic Stenosis
Condition
Cardiomyopathy, Hypertrophic
Intervention (Device)
Edwards SAPIEN XT transcatheter valve, Model 9300TFX
Lead sponsor
Edwards Lifesciences (class: industry)

Record details

Record id
cardio:ct-nct03225001
Content hash
cf08f9fb90ac07af45ed214c595648f6cdd60076fd6eb66655292bb0d7c48675